Vaccination against pandemic influenza A/H1N1v in England: A real-time economic evaluation

Vaccine

Volumn 28, Issue 12, 2010, Pages 2370-2384

  Baguelin, Marc ^a   Hoek, Albert Jan Van ^a   Jit, Mark ^a   Flasche, Stefan ^a,b   White, Peter J ^a,c   Edmunds, W John ^a,d  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Influenza; Mathematical Model; Vaccination

Indexed keywords

INFLUENZA VACCINE;

ARTICLE; CONSULTATION; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG EFFECT; ECONOMIC EVALUATION; EMERGENCY CARE; HEALTH PROGRAM; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFLUENZA; INFLUENZA VIRUS A H1N1; INTENSIVE CARE; MODEL; PANDEMIC; PRIORITY JOURNAL; UNITED KINGDOM; VACCINATION; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DISEASE OUTBREAKS; ENGLAND; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREGNANCY; SEASONS; VACCINATION; YOUNG ADULT;

EID: 77249123297     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.002     Document Type: Article

References (33)

1. Department of Health. Advice from the Joint Committee on Vaccination and Immunisation on swine flu vaccination. Friday 7 August 2009. Available at: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@ab/documents/digitalasset/dh_104372.pdf. (Accessed 30-10-09).
2. Department of Health. More than 11 million people in England will be offered it first. Available from: http://nds.coi.gov.uk/content/detail.aspx?NewsAreaId=2&ReleaseID=407719&SubjectId=16&AdvancedSearch=true. (Accessed 30-10-09).
3. Health Protection Agency. HPA weekly national influenza report. www.hpa.org.uk.
4. Fraser C., Donnelly C.A., Cauchemez S., et al. Pandemic potential of a strain of Influenza A (H1N1): early findings. Science May (2009)
5. Mossong J., Hens N., Jit M., et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 5 March (3) (2008) e74
6. Hens N., Ayele G.M., Goeyvarts N., et al. Estimating the impact of school closure on social mixing behaviour and the transmission of close contact infections in eight european countries. BMC Infect Dis (2009)
7. Directgov. Directgov: Find out school term dates. Available from: http://local.direct.gov.uk/LDGRedirect/index.jsp?LGSL=36. (Accessed 30-10-09).
8. National Institute for Health and Clinical Excellence. Updated guide to the methods of technology appraisal. June 2008. London: National Institute for Health and Clinical Excellence.
9. Curtis L. Unit Costs of Health and Social Care 2008. Kent: Personal Social Services Research Unit, University of Kent at Canterbury. Available from: http://www.pssru.ac.uk/uc/uc2008.htm. (Accessed 12-09-09).
10. Carrat F., Vergu E., Ferguson N.M., et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 167 April (7) (2008) 775-785
11. Kmietowicz Z. England to launch special flu service next week to take pressure off primary care. BMJ 339 (2009) b2932
12. Flusurvey. www.flusurvey.org.uk. (Accessed 16-12-09).
13. Baker M.G., Kelly H., and Wilson N. Pandemic H1N1 influenza lessons from the southern hemisphere. Eurosurveillance 14 October (42) (2009) pii:19370
14. Garske T., Legrand J., Donnelly C.A., et al. Assessing the severity of the novel influenza A/H1N1 pandemic. BMJ 339 (2009) b2840
15. McCormick A, Fleming D, Charlton J. Morbidity Statistics from General Practice, Fourth National Survey 1991-92, MB5. London: HMSO.
16. Melegaro A., and Edmunds W.J. The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. Eur J Epidemiol 19 4 (2004) 365-375
17. Health Protection Agency Epidemiology of new influenza A (H1N1) virus infection, United Kingdom, April-June 2009. Euro Surveill 2009 Jun 4;14(22).
18. Department of Health. NHS reference costs 2008. Department of Health; 2008.
19. Siddiqui M.R., and Edmunds W.J. Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerg Infect Dis 14 February (2) (2008) 267-274
20. Harris J.P., Jit M., Cooper D., and Edmunds W.J. Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease. Vaccine 25 May (20) (2007) 3962-3970
21. Department of Health. GP deal on swine flu vaccination: Department of Health - Public health. Available at: http://www.dh.gov.uk/en/Publichealth/Flu/Swineflu/DH_105132. (Accessed 30-10-09).
22. Department of Health. H1N1 Swine Flu Vaccination Programme: Information materials and vaccine schedule information. 22 October 2009. Available at: http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_107752.pdf. (Accessed 30-10-09).
23. GlaxoSmithKline. GSK: Results Summaries: Compounds. H1n1 Pandemic Influenza Vaccine. Available from: http://www.gsk-clinicalstudyregister.com/result_comp_list.jsp?compound=H1n1+Pandemic+Influenza+Vaccine. (Accessed 10-10-09).
24. Demicheli V., Di Pietrantonj C., Jefferson T., Rivetti A., and Rivetti D. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev 2 (2007) CD001269
25. Yang Y., Sugimoto J.D., Halloran M.E., Basta N.E., Chao D.L., Matrajt L., Potter G., Kenah E., and Longini Jr. I.M. The transmissibility and control of pandemic influenza A (H1N1) virus. Science 326 October (5953) (2009) 729-733 Epub 2009 September 10
26. Medlock J., and Galvani A.P. Optimizing influenza vaccine distribution. Science 325 September (5948) (2009) 1705-1708 Epub 2009 August 20
27. Maurer J., Harris K.M., Parker A., and Lurie N. Does receipt of seasonal influenza vaccine predict intention to receive novel H1N1 vaccine: evidence from a nationally representative survey of U.S. adults. Vaccine 27 September (42) (2009) 5732-5734
28. Henrich N., and Holmes B. The public's acceptance of novel vaccines during a pandemic: a focus group study and its application to influenza H1N. Emerging Health Threats J 2 (2009) e8
29. World Health Organisation. Experts advise WHO on pandemic vaccine policies and strategies. Pandemic (H1N1) 2009 briefing note 14. Available at: http://www.who.int/csr/disease/swineflu/notes/briefing_20091030/en/index.html. (Accessed 10-10-09).
30. Galli G., Hancock K., Hoschler K., et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc Natl Acad Sci USA 106 (May) 19 (2009) 7962-7967
31. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary 58. September 2009 edition. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2006.
32. Donaldson L.J., Rutter P.D., Ellis B.M., Greaves F.E.C., Mytton O.T., Pebody R.G., and Yardley I.E. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ 339 (2009) b5213 10.1136/bmj.b5213
33. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon, M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010; doi:10.1016/S0140-6736(09)62126-7.